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Summary
Lectin-like, oxidized low-density lipoprotein (LDL) re-
ceptor 1, LOX-1, is the major receptor for oxidized
LDL (OxLDL) in endothelial cells. We have determined
the crystal structure of the ligand binding domain of
LOX-1, with a short stalk region connecting the do-
main to the membrane-spanning region, as a homodi-
mer linked by an interchain disulfide bond. In vivo as-
says with LOX-1 mutants revealed that the “basic
spine,” consisting of linearly aligned arginine resi-
dues spanning over the dimer surface, is responsible
for ligand binding. Single amino acid substitution in
the dimer interface caused a severe reduction in
LOX-1 binding activity, suggesting that the correct di-
mer arrangement is crucial for binding to OxLDL.
Based on the LDL model structure, possible binding
modes of LOX-1 to OxLDL are proposed.
Introduction
Oxidative stress plays a central role in atherogenesis
(Kita et al., 2001). Oxidative stress modifies low-density
lipoprotein (LDL), and the oxidized LDL (OxLDL), as a
marker of the atherosclerosis, induces endothelial dys-
function and injury (Mehta, 2004). Endothelial dysfunc-
tion is believed to be a crucial early step in the develop-
ment of atherosclerosis. Endothelial cells internalize
OxLDL by cell surface receptors, as in the process by
which macrophage and smooth muscle cells uptake
OxLDL by a variety of scavenger receptors, including
SR-AI/II, CD36, and SR-BI (Steinbrecher, 1999). These
classical scavenger receptors are either absent or
found at very low levels on endothelial cells (Mehta,
2004); the endothelial cells possess a specific type of
OxLDL receptor. Lectin-like OxLDL receptor 1 (LOX-1)
has been identified as a OxLDL receptor primarily in
endothelial cells (Sawamura et al., 1997).
LOX-1 expression is upregulated in pathological con-
ditions affecting the vasculature, such as hypertension,
diabetes, and atherosclerosis (Chen et al., 2000; Ka-*Correspondence: tate@beri.or.jptaoka et al., 1999; Nagase et al., 1997). The expression
of LOX-1 affects a variety of gene expression, including
adhesion molecules, endothelial constitutive nitric ox-
ide synthetase (eNOS), and monocyte chemoatractant
protein-1 (MCP-1) (Li et al., 2002a; Mehta et al., 2001).
OxLDL causes apoptosis in human coronary artery en-
dothelial cells (HCAECs) with the associated upregula-
tion of LOX-1 expression (Li et al., 1998). Intriguingly, a
specific antisense to LOX-1 mRNA decreased apopto-
sis (Li and Mehta, 2000). Immunostaining showed that
the most prominent expression of LOX-1 was observed
in the endothelial cells of atherosclerotic lesions (Chen
et al., 2000). These observations indicate that LOX-1
plays a critical role in endothelial dysfunction and injury,
leading to initiation and progression of atherosclerosis
(Chen et al., 2002; Kita, 1999).
The LOX-1 gene has been mapped to the genetic re-
gion known as the NK-gene complex (NKC) (Aoyama et
al., 1999), which mainly encodes receptors associated
with natural killer cells (NK cells) (Yokoyama and Plou-
gastel, 2003). As with all lectin-like NK cell receptors
encoded in the NKC, LOX-1 is a membrane protein with
a type II orientation and displays sequence homology
to C-type animal lectins, which bind carbohydrates in a
Ca2+-dependent manner (Chen et al., 2002; Drickamer,
1999; Zelensky and Gready, 2003). LOX-1, like other NK
cell receptors, consists of four domains: a short N-ter-
minal cytoplasmic domain, a single transmembrane do-
main, a NECK domain or stalk, and a C-type lectin-like
domain (CTLD) at the C-terminal end (Figure 1A). The
CTLD in LOX-1 has been confirmed experimentally to
be a ligand binding domain (Chen et al., 2001; Shi et
al., 2001).
In this study, we report the crystal structure of the
LOX-1 ligand binding domain. The structure, which in-
cludes only a small region of the NECK domain, is the
disulfide-linked homodimer that is the form present on
the cell surface. This adds the example of a disulfide-
linked dimer structure for proteins in group V of the
CTLD family, to which hetero- or homodimer-form-
ing, CTLD-containing NK receptors belong (Drickamer,
1999). In vivo functional assays with LOX-1 mutants re-
vealed that the linearly aligned basic residues at the
dimer surface are responsible for ligand binding. We
refer to this characteristic structural feature as the “ba-
sic spine.” In addition, single amino acid substitution of
the residue W150 at the dimer interface resulted in a
more drastic reduction in binding activity than single
amino acid changes at the dimer surface. The combina-
tion of structural data and mutational analysis demon-
strates the importance of the basic spine on the dimer
surface in terms of LOX-1 binding activity. Based on the
consensus model structure of LDL, the possible role of
the basic spine in OxLDL binding is discussed.
Results
Overall Architectures in Two Crystals
We prepared three forms of the extracellular region of
LOX-1 (Figure 1A): the whole extracellular domain, in-
Structure
906Figure 1. Human LOX-1 Domain Structure and Its Disulfide-Linked Homodimer Formation
(A) Schematic representation of the primary structure of human LOX-1. Four domains are shown by different rectangles: TM, transmembrane
domain; CTLD, C-type lectin-like domain. Cysteine residues with intrachain disulfide bonds are highlighted.
(B) Sequence alignment of the CTLDs. The first group contains six LOX-1 orthologs. The second group includes NKDs for natural killer (NK)
cell receptors. The sequence of the carbohydrate recognition domain (CRD) of the true C-type lectin MBP-A constitutes group 3. Residues
strictly conserved among group 1 are shown in boxes. Homologous residues to LOX-1 CTLD found in the sequences of groups 2 and 3 are
boxed. Conserved cysteine residues are marked in red. Basic residues in LOX-1 CTLD, which constitute the basic spine, are marked in blue.
The observed secondary structure organization of CTLD in the crystal structure of the LOX-1 disulfide-linked dimer is shown at the top; the
green arrow and the red box are the β strand and the α helix, respectively. Secondary structure of rat MBP-A, a canonical CTLD structure, is
shown below. The green and red boxes represent the β strand and the α helix, respectively (Weis et al., 1991). The gray boxes in the bottom
line represent the loop regions that constitute the long loop region, LLR, commonly found in all CTLDs. The loop numbers denoted as L1–L4
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907cluding CTDL and the NECK domain (residues 61–273);
a fragment of CTLD having a short (14 residue) NECK
domain (CTLD-NECK14, residues 129–273); and the
CTLD domain only (CTDL, residues 143–273). Each
fragment was expressed in Escherichia coli and was
obtained by in vitro refolding from inclusion bodies.
Two of the recombinant proteins, namely, the whole
extracellular domain and CTLD-NECK14, formed ho-
modimers connected by an interchain disulfide bond at
C140, as found in the native LOX-1 on the cell surface
(Xie et al., 2004). Disulfide bond formation in LOX-1 was
confirmed by SDS-PAGE analysis of samples prepared
under reduced and nonreduced conditions (Figure 1C).
In the absence of the NECK domain, CTLD does not
form a stable homodimer in solution, as revealed
by analytical ultracentrifugation (Figure 1D). Thus, the
NECK domain appears to be essential for maintaining
the dimer structure. We crystallized all three LOX-1
fragments. The crystal of the whole extracellular do-
main did not give good X-ray diffraction data. We then
focused on the LOX-1 CTLD and the CTLD-NECK14
fragments in the subsequent structural work.
The CTLD fragment (residues 143–273) was crystal-
lized in an acidic solution consisting of 0.1 M citrate
buffer (pH 3.6–3.8). The crystal we obtained belongs to
the space group P212121 with unit cell dimensions of
a = 56.79 Å, b = 67.57 Å, and c = 79.02 Å. Two CTLD
molecules were in the asymmetric unit (Figure 2A). The
structure of CTLD was solved with multiwavelength
anomalous diffraction (MAD) by using a SeMet-CTLD
and was refined to 1.8 Å resolution (Table 1).
The CTLD-NECK14 crystals were obtained under
near physiological conditions (10 mM Tris-HCl [pH 7.5],
400 mM NaCl). These crystals belong to the space
group C2 with a = 70.86 Å, b = 49.54 Å, c = 76.73 Å,
and β = 98.59°. The structure of CTLD-NECK14 was
determined at 2.4 Å resolution by molecular replace-
ment by using the structure of LOX-1 CTLD solved with
the above-mentioned CTLD crystal (Table 1).
The LOX-1 CTLD forms a crystallographic dimer. The
relative orientation of the subunits in the LOX-1 CTLD
dimer is almost inverted compared with that found in
the CTLD-NECK14 covalently linked dimer (Figures 2A
and 2B). The crystallographic dimer structure for the
LOX-1 CTLD shows the interchain parallel arrangement
of the most N-terminal β strand, β0, at the dimer inter-
face (Figure 2A). The disulfide-linked CTLD-NECK14 di-
mer displays a similar arrangement to those commonly
found in the crystallographic dimer for the CTLDs of
natural killer receptors, which are so called natural killer
domains (NKDs) (Figure 2B). In LOX-1 CTLD-NECK14,
the β0 strand forms interchain antiparallel β sheets
through three hydrogen bonds and two salt bridges, the molecule in the neighboring crystal unit. Using 128
are defined from the crystal structure of rat MBP-A (Weis et al., 1991). Residues in purple boxes in the MBP-A sequence coordinate the Ca2+
ion required in carbohydrate binding.
(C) SDS-PAGE of refolded LOX-1 proteins. CTLD, NECK14, and ECD denote truncated recombinant versions of LOX-1, CTLD (142–273),
CTLD-NECK14 (129–273), and the whole extracellular domain (61–273), respectively. The samples treated with β-mercaptoethanol to cleave
the disulfide bonds were run in the lanes denoted as “reduced.” Lanes shown as “nonreduced” indicate samples in which the disulfide bonds
were retained.
(D) The results of the analytical ultracentrifugation for the LOX-1 proteins; CTLD, CTLD-NECK14, and the whole extracellular domain (ECD).
Curve fitting to the experimental data with a single component model and the residuals of the observed data from the fit model curve are
shown. The number of subunits in a molecule determined by the analysis is shown in each sedimentation profile.which define the specific relative orientation of the two
subunits (Figure 3B). This interconnected β0 strand
contains a conserved sequence motif (W-I/L-W-H)
among the six LOX-1 orthologs (Figure 1B). A similar
motif (W-X-X-Y/F), in which the second residue is hy-
drophobic, is conserved in the NKDs (Natarajan et al.,
2002) (Figure 1B). The interchain disulfide bond in CTLD-
NECK14 was chemically confirmed, but there was no
interpretable electron density to identify it, suggesting
that the short NECK domain in CTLD-NECK14 is intrin-
sically mobile.
There are different numbers of residues seen in the
two independent copies of NECK. The longer NECK is
observed from A136, and the shorter one is seen from
A141. The longer NECK is more visible because of crys-
tal contact. Both copies in the CTLD-NECK14 covalent
dimer structure were visible up to L270.
The LOX-1 CTLD Fold
As predicted by amino acid sequence similarity, the
LOX-1 ligand binding domain displays the salient fea-
tures of the CTLD fold (Figure 2C). There are two types
of CTLD structure with significant differences in the ori-
entation of the second α helix, α2. Ly49A, as a repre-
sentative structure in the atypical class, shows a dif-
ferent α2 orientation from that found in a canonical
CTLD structure of MBP-A (Figure 2C). The superposi-
tion of LOX-1 CTLD onto Ly49A results in a 1.2 Å root
mean square (rms) deviation for 92 Cα pairs. LOX-1
CTLD thus belongs to the rare type of the CTLD fold
represented by Ly49A (Figure 2C).
LOX-1 CTLD contains all of the main secondary
structure elements found in other members of the C-type
lectin-like superfamily (Figure 2B). Strand β2 forms a
short β hairpin with the β2a strand. There is an addi-
tional parallel β sheet located between β2b and β4 (Fig-
ure 2B). The upper part of the molecule is characterized
by a segment of polypeptide, located between strands
β2a and β2b, that lacks regular secondary structure.
This connecting region is called the long loop region
(LLR), a variable segment involved in specific ligand
binding for each CTLD (Zelensky and Gready, 2003).
Like NKDs, the LLR structure in LOX-1 CTLD differs
substantially from the corresponding region in the ca-
nonical C-type lectins in that it lacks the Ca2+ binding
site that is critical for carbohydrate recognition do-
mains (CRD) (Figure 2C). In fact, LOX-1 does not require
Ca2+ for its ligand binding. A notable structural feature
of LOX-1 is that both ends of the LLR are fixed by anti-
parallel (β2–β2a) and parallel (β2b–β4) β sheets (Fig-
ure 2B).
One copy of the CTLD-NECK14 structure contacts
Structure
908Figure 2. Two Crystal Forms of LOX-1 and the Structural Comparison of the CTLD with Other Members of the C-Type Lectin-like Family
(A) Structure of the crystallographic dimer of LOX-1 CTLD (143–273). The crystal was obtained from acidic solution. Two molecules in a unit
cell are shown as a different color. The secondary structures are denoted by the symbols defined in Figure 1B. The intrachain disulfide bonds
are shown by red balls-and-sticks.
(B) Structure of the LOX-1 CTLD-NECK14 (129–273), which is in the disulfide-linked dimer form. Each subunit in the dimer is shown in a
different color. Due to the structural flexibility of the N-terminal region, only one C140 was observed in the electron density map. The possible
interchain disulfide bond is shown by red ball-and-stick representation.
(C) Structure of LOX-1 CTLD and comparison with other members of the C-type lectin-like family. Ribbon diagrams of the LOX-1 CTLD (left),
Ly49A (center), and MBP-A (right) are shown in a common orientation. The Ca2+ ions bound to MBP-A are shown as gray spheres. The loops
in the long loop region, LLR, involved in Ca2+ coordination are labeled in the structure of MBP-A. Two α helices in the CTLDs are labeled as
α1 and α2. In both LOX-1 and Ly49A, the α2 helix is rotated by about 20°, as compared with MBP-A and most other members of the C-type
lectin-like family. Disulfide bonds in each CTLD are shown by red ball-and-stick representation. PDB codes for Ly49A and MBP-A are 1QO3
(Tormo et al., 1999) and 2MSB (Weis et al., 1992), respectively. Secondary structure elements were defined by using procedures in MOLMOL
according to the Kabsch/Sander algorithm (Koradi et al., 1996). All figures were prepared by the program MOLSCRIPT (Kraulis, 1991).Cα carbons in residues 143–270 (Figure S1; see the r
sSupplemental Data available with this article online), we
showed that superposition of a copy of CTLD-NECK14 a
sthat does not show the crystal contact with a copy in
the LOX-1 CTLD crystallographic dimer showed 0.5 Å i
arms deviation. The corresponding value for the other
copy of CTLD-NECK14 having the crystal contact was e
n1.2 Å. We concluded that the monomer unit of the
LOX-1 ligand binding domain retains essentially the b
Ssame structure in the different crystal conditions. There-
fore, the LLR forms a specific conformation, despite the r
2lack of any regular secondary structure.
The LOX-1 CTLD-NECK14 and the CTLD crystals L
cwere obtained under neutral and acidic pH conditions,espectively. The above-mentioned structural compari-
ons may also mean that solution pH differences do not
lter the ligand binding domain structure of LOX-1. This
uggests that the LOX-1 ligand binding domain retains
ts structure in the endosome where the pH is in the
cidic range (<pH 6) (Murphy et al., 1984). Although
ach ligand binding domain per se does not show sig-
ificant structural change, we cannot rule out the possi-
ility of pH-induced dimer disarrangement in LOX-1.
uch a change is inferred from the different dimer ar-
angements found in the two crystal structures (Figures
A and 2B). The possible dimer disarrangement of
OX-1 may be related to the proposed structural
hange of the LDL receptor, which is believed to be
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909Table 1. Data Collection and Crystallographic Refinement
CTLD (Acidic Condition)
Data Collectiona CTLD-NECK14 SeMet1 SeMet2 (Peak) SeMet2 (Rdge) SeMet2 (Temote)
Wavelength (Å) 1.0000 1.0000 0.9792 0.9794 0.9762
Resolution (Å) 37.9–2.40 50.0–1.78 50.0–1.96 50.0–1.96 50.0–1.96
Unique reflections 10,449 33,424 25,180 25,265 25,653
Completeness (%) 99.3 (99.3) 99.6 (99.7) 100.0 (99.9) 100.0 (99.9) 100.0 (99.9)
Rmerge (I)b (%) 8.1 (36.4) 5.3 (39.5) 7.1 (22.7) 6.4 (25.2) 6.2 (22.6)
MAD Phasing
Number of sites 6 6 6
Phasing powerc (centric/acentric) 1.43/1.09 1.32/0.58 0.00/1.07
Figure of meritd (centric/acentric) 0.80/0.77
Structure Refinement CTLD-NECK14 CTLD (SeMet1) CTLD (SeMet2)
Resolution (Å) 37.0–2.40 30.0–1.78 30.0–1.96
Reflections (cryst/free) 9,824/546 30,428/1,597 23,656/1,230
Protein/solvent atoms 2,111/52 2,292/215 2,264/177
Rcryst/Rfreee (%) 20.0/27.5 20.9/23.0 20.8/24.4
Rmsd (bond/angle) 0.009 Å/1.4° 0.005 Å/1.2° 0.005 Å/1.2°
a Values in parentheses indicate statistics for the last shell.
b Rmerge= ΣiΣj|<Ij> − Iij|/ΣiΣjIij, where <Ii> is the mean intensity of the ith unique reflection, and Iij is the intensity of the jth observation.
c Phasing power = <F(H)>/E, where <F(H)> is the rms amplitude of the heavy atom structure factor, and E is the residual lack of closure error.
d Figure of merit = <ΣP(α)exp(iα)/ΣP(a)>, where P(α) is the phase probability at the angle α.
e Rfree was calculated by using 5% of total reflections, which were chosen randomly and omitted from the refinement.induced by exposure to the endosomal pH (Rudenko et
al., 2002).
LOX-1 ligand binding domain has three intrachain di-
sulfide bonds (Figure 2B), two of which (C172–C254
and C243–C256) are characteristically invariant disul-
fide bonds found in all members of the C-type lectin-
like domains (Figure 1B). The third disulfide bond is
located at C144–C155, which maintains the short anti-
parallel β sheet between β0 and β1. This short antipar-
allel β sheet is connected by four hydrogen bonds
among backbone atoms (Figure 3A). In addition, W150
N1 is hydrogen bonded to the carbonyl oxygen of
G152 in the same chain (Figure 3A). This side chain-
backbone hydrogen bond contributes to maintaining
the proper orientation of W150 and H151. These resi-
dues subsequently form interchain hydrogen bonds
and salt bridges, which define the specific dimer ar-
rangement (Figure 3B).
In all C-type lectin-like domain structures, the N and
C termini are spatially closed (Drickamer, 1999). In
LOX-1 CTLD, C155 in the β1 strand is hydrogen bonded
to K266 located in the β5 strand, which maintains the
N and C termini in spatial proximity (Figure 3A). The
antiparallel β sheet between β1 and β5 constitutes the
proper overall CTLD fold. Homologous sequences are
found in the C-terminal region of all six LOX-1 orthologs
(Figure 1B). Machida and coworkers have shown that
the deletion of seven residues, KANLRAQ (267–273),
from the C terminus of human LOX-1 leads to improper
folding within the cell, as revealed by the altered N-glyco-
sylation pattern of the expressed protein (Shi et al.,
2001). Deletion of nine residues QKKANLRAQ (265–273)
from the C terminus destroyed the structure, and the
expressed protein was not present on the cell surface
(Shi et al., 2001). These results suggest that the C-ter-
minal homologous region is essential for maintaining
the active CTLD fold. This is consistent with the LOX-1ligand binding domain structure, in which the hydrogen
bond between C155-K266 maintains the conserved
antiparallel β sheets between β1 and β5. Weakening the
C155-K266 hydrogen bond, by deletion of the neigh-
boring C-terminal sequence KANLRAQ (residues 267–
273), or eliminating it by deletion of QKKANLRAQ (resi-
dues 265–273), results in improper folding of the LOX-1
ligand binding domain.
The LOX-1 CTLD Homodimer
Human LOX-1 exists as a disulfide-linked homodimer
at C140 on cell surfaces (Xie et al., 2004). The formation
of a disulfide-linked dimer is the common structural
feature in the C-type lectin-like NK receptors (Natarajan
et al., 2002). Unlike C-type lectin-like NK receptors, this
interchain disulfide bond is not conserved among other
LOX-1 orthologs. In addition, this interchain linking
does not seem to be essential for the recognition of
modified LDL by human LOX-1. The C140S mutation of
human LOX-1 retained the ability to bind modified LDL,
although it showed reduced binding to bacteria (Xie et
al., 2004).
The high level of sequence similarity of the NECK to
a myosin heavy chain suggests that the LOX-1 NECK
should form a parallel coiled-coil structure as in the my-
osin tail (Lupas, 1996). The presumed overall structure
for the complete extracellular domain of LOX-1 is
shown schematically (Figure 3C). Secondary structure
predictions suggest, however, that the α-helical region
may not extend through the entire NECK domain, there
being a break at the center of the NECK domain. This
break would confer a flexible arrangement for the
C-terminal ligand binding domains on the cell surface.
Intriguingly, this predicted helix break is close to the
cleavage site for generating a soluble form of LOX-1,
mediated by an unknown protease on the cell surface
(Murase et al., 2000).
Structure
910Figure 3. Hydrogen Bonding Network in LOX-1 and Its Dimer Surface Structure
(A) Intrachain hydrogen bonding network in the LOX-1 CTLD.
(B) Hydrogen bonds connecting the two subunits of the LOX-1 CTLD dimer.
(C) Schematic drawing of the entire architecture of LOX-1. The C-terminal dimer CTLD is the crystal structure determined in this work. The
NECK domain, residues 61–139, is drawn as a coiled-coil structure predicted according to its sequence characteristics. In this figure, a
possible break in the coiled-coil structure and the N-terminal cleavage positions to generate the soluble form of LOX-1, which were deter-
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911ment. In turn, this will disrupt the basic spine structureligand recognition.
mined for bovine LOX-1 (Murase et al., 2000), is shown. Two boxes on the CTLD crystal structure indicate the view positions for (A) and (B).
(D) Ribbon representation of the CTLD dimer structures for LOX-1, NKG2D, and Ly49A. The latter two dimers are the crystallographic dimers
without covalent linkage.
(E) The surface charge distribution on the dimer surface with the corresponding views of the dimer structures shown in the ribbon representa-
tion. Contact area found for NKD2D-MICA (PDB code: 1HYR) (Li et al., 2001) and Ly49A-H-2D (PDB code: 1QO3) (Tormo et al., 1999) complex
structures are drawn on their surfaces with green lines. Another contact region in the Ly49A structure in the complex with H-2Dd is drawn
with a red line. The contact areas for NKG2D and Ly49A were identified with the maximum distance range for contacting atoms 4.5 Å by the
program GRASP (Nicholls et al., 1991). All surface colors drawn on the solvent accessible surface represent −10 kBT−1 (red) to +10kBT−1 (blue)
by using the program GRASP (Nicholls et al., 1991).The LOX-1 CTLD per se does not form a stable ho-
modimer (Figure 1D). The crystal structure of CTLD-
NECK14 has shown that the interchain disulfide bond
helps the proper dimer formation of the LOX-1 CTLDs.
In other LOX-1 orthologs, the CTLD dimer arrangement
is defined by the coiled-coiled structure formed in the
NECK domain, which functionally compensates for the
loss of the interchain disulfide bond. This also explains
the minimal impact on function upon loss of the interchain
disulfide bond in human LOX-1 (Xie et al., 2004).
The Ligand Binding Surface of LOX-1—Basic
Spine Structure
The dimer surface contains the most variable part of
CTLD, the LLR, in terms of structure and amino acid
sequence. This variability explains the importance of
this part of the molecule in selective ligand recognition.
In Ly49A, this region contains the binding site for its
ligand, MHC class I molecules (Tormo et al., 1999). The
corresponding region in NKG2D is also known to be
important for ligand binding (Li et al., 2001, 2002b;
McFarland et al., 2003; Radaev et al., 2001). The bind-
ing surfaces for NKG2D and Ly49A are well charac-
terized in their complex structures with ligands. The
binding regions are marked on their surface charge
maps (Figure 3E). Each NKD uses the particular surface
area to enable specific ligand recognition.
Sequence and structural comparisons of the C-type
lectin-like family proteins revealed that the LLR plays
a homologous role to that of the hypervariable loop
of the immuoglobulin domain (Zelensky and Gready,
2003). The LLR is, thus, a structurally independent part
of CTLD, suggesting that the LLR is a flexible unit for
adaptive evolution (Zelensky and Gready, 2003). The
observed diversity in the dimer surface structure can be
ascribed to sequence variation in the LLR (Figure 1B).
The characteristic LLR sequence of LOX-1 gives a
distinctive charge distribution at the ligand binding sur-
face. There is a linear arrangement of basic residues
crossing over the dimer surface of LOX-1, which we call
the “basic spine” (Figure 3E). Arginine residues in the
LLR and R248 form the basic spine (Figures 1B and 3E).
Acidic spots, arising from E254 in each subunit, are
also present, although these do not appear to influence
binding activity (Shi et al., 2001) (Figure 3E). By contrast
with other NKDs, the LOX-1 dimer surface is primarily
hydrophobic (Figure 3E). LOX-1 preferentially binds to
negatively charged molecules, including OxLDL, the
apoptotic cell whose surface is rich in negatively
charged phosphatidyl serine moieties, and poly anion
molecules like poly inosinic acids (Chen et al., 2002).
The basic spine appears to be responsible for specificRole of the Residues in the Basic Spine
We explored the biological significance of the basic
spine on the LOX-1 dimer surface by introducing single
amino acid substitutions.
The ability of LOX-1 mutants to take up acetylated
LDL (AcLDL) into living cells was assayed by micro-
scopic observation (Figure 4). AcLDL was used as an
alternative ligand to OxLDL, which shows comparable
affinity to LOX-1 (Shi et al., 2001), in order to avoid am-
biguous effects from variations in the extent of OxLDL
oxidation (Lougheed and Steinbrecher, 1996; Yoshida
et al., 1998). In this assay, the amount of incorporated
AcLDL directly reflected the binding activity of LOX-1,
which was confirmed by independent analysis as de-
scribed previously (Chen et al., 2001). The mutants
R208N, R229N, and R248N were expressed normally on
the cell surface but showed reduced AcLDL uptake,
thus showing their reduced binding activities. R231N
displayed no detectable AcLDL binding activity. As a
control, H226A, which is located outside the basic
spine, showed no reduction in binding activity. Each
Arg residue in the basic spine plays a significant role in
LOX-1 ligand binding (Figure 3E). Interestingly, R209N
had little effect on the binding activity, although the
R208N was effective (Figure 4). This is because R209 is
located beneath the binding surface.
Except for R231N, single amino acid changes in the
basic spine showed only a moderate effect on ligand
binding. This binding feature is consistent with that for
the scavenger receptor, SR-A. In the case of SR-A, the
substitution of more than two lysine residues in a con-
served basic amino acid cluster in the collagen-like do-
main was required to abolish the binding to OxLDL (Doi
et al., 1993).
Mutation of a Residue at the Homodimer Interface
Our mutant analyses show that residue W150, located
at the dimer interface, plays a major role in the LOX-1
binding activity. The mutation W150A results in an al-
most complete loss of binding activity to AcLDL (Figure
4). Except for R231, this result contrasts with the mod-
erate effect of single amino acid changes to the basic
spine. The LOX-1 dimer structure shows that the W150
contributes not only to dimer formation but also to
maintaining the proper CTLD fold through inter- and in-
trachain hydrogen bonds (Figures 3A and 3B). Loss of
the W150 side chain to the G152 backbone hydrogen
bond should deform the β0 strand that makes the in-
terchain antiparallel β sheet (Figure 3B). Because the
interchain hydrogen bonds define the specific orienta-
tion of the two subunits of dimer, disturbance of this
hydrogen bond network may induce dimer disarrange-
Structure
912Figure 4. Effect of Amino Acid Substitutions in Human LOX-1 on Ligand Uptake
In the left column, the substituted amino acids are shown by yellow sphere representation on the crystal structure of the CTLD-NECK14
dimer. Phase contrast images of the cells are shown in the second column. The bar in the bottom panel indicates a length of 20 m. The two
columns to the right show the corresponding fluorescence image of the cells in the same view as that used for the phase contrast micrograph.
The fluorescence images for CFP-LOX-1 (excitation 436 nm) and DiD-AcLDL (excitation 620 nm) are shown in the left and right panel, respec-
tively.on the ligand binding surface, which should result in a W
lsevere reduction of LOX-1 ligand binding activity.
There is a small, empty cavity in the LOX-1 dimer t
Linterface. The cavity, 114 Å3 in volume, is formed by
hydrophobic residues, including P143, C144, P145, s148, I149, and W150 (Figure 5A). Although the bio-
ogical role of this cavity is not immediately apparent,
he cavity-forming residues are conserved among all
OX-1 orthologs, with the exception of I149, which is
ometimes replaced by leucine (Figure 1B). Substitu-
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913Figure 5. The Empty Cavity in the Dimer Interface of LOX-1
(A) Empty cavity located at the dimer interface in the LOX-1 disul-
fide-lined dimer structure. The surrounding residues of the cavity
are shown as bold lines.
(B) Possible effect of the W150A mutation on the basic spine struc-
ture on the LOX-1 ligand recognition surface. The W150A mutation
may resize the empty cavity in the dimer interface, which subse-
quently disarranges the dimer, resulting in the disruption of the ba-
sic spine structure. The disrupted basic spine structure should lead
to severe reduction of the binding ability to ligands.
(C) A plausible representation of the entire structure of LOX-1 at
the cell surface, based on the crystal structure for CTLD and the
model structure for the NECK. Modeling was performed by using
the myosin heavy chain coiled-coil structure, which shows a high
level of sequence homology to the NECK region.During oxidation of LDL, there is a progressive de-
(D) Scale comparison between the the OxLDL particle and LOX-1
dimer. The assembled structure of LOX-1 is drawn according to
the results of cell biology studies that showed LOX-1 to exist as a
hexamer on the cell surface (Xie et al., 2004). The diameter of
OxLDL was estimated from cryoelectron microscopic observation
of the LDL particle (Segrest et al., 2001). In this comparison, it is
assumed that no significant structural alterations are induced by
oxidation to the LDL particle.tion of W150, which is located at the bottom corner of
the empty cavity (Figure 5A), with an alanine residue
may lead to disarrangement of the dimer subunits by
closing the bottom of the empty cavity. This possible
disarrangement of the dimer, induced by cavity resiz-
ing, also facilitates the disruption of the basic spine on
the binding surface. Indeed, this could explain the se-
vere reduction of binding activity of the W150A mutant
for OxLDL (Figure 5B).
Discussion
Basic Spine Structure for the Ligand Recognition
The structural data presented in this paper show that
LOX-1 possesses a basic spine structure across its li-
gand recognition surface that is predicted to play an
essential role in OxLDL binding. There is a paucity of
structural data for LDL, which consists of lipids and
apolipoprotein B-100 (apoB-100), a single polypeptide
comprising about 4,500 residues that wraps the lipid
particle. The consensus model reveals that apoB-100
has a pentapartite domain structure, NH3-βα1-β1-α2-
β2-α3-COOH. The α and β domains are mainly com-
posed of amphipathic α helices and β sheets, respec-
tively (Segrest et al., 2001) (Figure S2A). The βα1
domain is thought to be a globular domain, based on
homology to lipovitellin (Segrest et al., 2001). The am-
phipathic β1 and β2 domains display sequence charac-
teristics typical for that of irreversible lipid association
(Segrest et al., 2001). However, the α2 and α3 domains
show similar sequence properties to that of an ex-
changeable apolipoprotein, such as apoA-I and apoE,
and are assumed to be flexible domains with reversible
lipid affinity (Segrest et al., 2001). From the size of the
surface area of LDL, the approximate number of amphi-
pathic α helices has been estimated to range from 51
to 65 according to the LDL subclasses (Segrest et al.,
2001), suggesting that LDL has amphipathic α helices
on its surface (Figure S2B). The basic spine structure
provides an appropriate platform for interaction with
the α helix in which at least 37 residues are required for
full contact (Figure 6A). Thus, we envisage that LOX-1
preferentially binds to an amphipathic α helix on the
LDL surface.
LOX-1 assembles on the cell surface as at least a
hexamer that comprises three homodimeric LOX-1
molecules in binding to OxLDL (Xie et al., 2004). Com-
paring the size of the dimer surface of LOX-1 with the
diameter of LDL, it seems reasonable that LOX-1 binds
to the OxLDL as an assembly (Figures 5C and 5D). The
amphipathic α helices on LDL can act as multiple bind-
ing sites for LOX-1 assembly on the cell surface.
Structure
914Figure 6. Possible Binding Mode of LOX-1 to
apoB-100 in LDL
(A) A model complex structure between the
LOX-1 dimer ligand recognition domain and
an α helix. The N atoms of the arginine resi-
dues in the basic spine are drawn with blue
spheres. The right figure is drawn from the
view rotated by 90° to that of the left figure.
(B) A helical-wheel presentation of the 22
residue consensus sequence for the 9 in-
ternal repeats found in apoB-100 by the iter-
ative alignment procedure (De Loof et al.,
1987). The circle colors represent the residue
characters: yellow, nonpolar; green, polar;
red, acidic; blue, basic. The consensus se-
quence shows amphipathic α-helical char-
acter with a negatively charged surface ex-
posed to the solvent.crease in the number of lysine -amino groups. The oxi- m
tdation of polyunsaturated fatty acids can form alde-
hydes that modify these amino groups to produce c
bmalondialdehyde and 4-hydroxynoneal (Stocker and
Keaney, 2004). The lysine amino groups are also cova-
tlently modified by phospholipids (Gillotte et al., 2000).
The blocking of lysine -amino groups with simulta- d
lneous fatty acid oxidation, giving hydroxyl fatty acids,
generates negatively charged LDL (Gillotte et al., 2000; a
gStocker and Keaney, 2004). LOX-1 binds to AcLDL
with comparable affinity. Acetylation blocks the lysine c
n-amino groups without any side reactions involving lip-
ids, thus also generating negatively charged LDL. g
gWe propose a model involving a reduced positive
charge as a possible explanation for the specific i
hLOX-1 binding to oxidized and acetylated LDLs. Hence,
the reduced surface positive charge of LDL accelerates m
dLOX-1 binding due to a reduction of repulsive charges
on the basic spine. LDL comprises the following content L
of charged residues: D (5.1%), E (6.5%), K (7.8%), and
R (3.3%), giving an almost neutral total charge. The e
tblocking of the -amino groups of lysine residues af-
fects the total LDL charge, which accelerates LOX-1 r
binding to the surface amphipathic helices. Sequence
analysis of apoB-100 has shown the presence of nine t
brepeated amphipathic helical regions consisting of 22
residues (De Loof et al., 1987); the consensus repeating t
esequence is DFIDEFNEKLKDLSDQLNDFLN. The 22
residue sequence is shown as a helical wheel diagram L
yin Figure 6B. Interestingly, this gives a negatively
charged surface on the opposite side to the membrane L
ebound hydrophobic region. The basic spine of LOX-1ust recognize the repeating helices on the LDL
hrough electrostatic interactions. The reduced positive
harge model consistently explains why AcLDL is
ound by LOX-1.
Another explanation for the LOX-1-specific binding
o OxLDL is the phospholipid conjugation model. Oxi-
ized phospholipids link to lysine amino groups (Gil-
otte et al., 2000), and the conjugated lysine residues
re then decorated with negatively charged phosphate
roups. In apoB-100, there are well-defined positively
harged amphipathic α helices in the β2 domain. The
umber of residues in the α helices are 22, 39, and 33,
iving a comparable size to that of the basic spine (Se-
rest et al., 2001). Phospholipid conjugation to lysines
n the basic helices provides the negatively charged
elices recognized by the basic spine of LOX-1. This
odel may explain the LOX-1 binding to OxLDL, but it
oes not readily explain the observed AcLDL activity to
OX-1 binding.
It is difficult to evaluate the significance of the mod-
ls at present, but both mechanisms may occur simul-
aneously to generate the modified LDL that is actively
ecognized by LOX-1.
Experiments with delipidated OxLDL have shown
hat LOX-1 recognizes modified apoB-100 in OxLDL,
ut cannot rule out the possibility that LOX-1 also binds
o modified lipids firmly linked to apoB-100 (Moriwaki
t al., 1998). Although it is generally accepted that
OX-1 recognizes the protein moiety of OxLDL, it is not
et known whether oxidized phospholipids bind to
OX-1 (Mehta, 2004). Taking into account these consid-
rations, with the exception of apoB-100, which is
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915known to be cleaved in the maximally oxidized particle
(Fong et al., 1987), several types of fatty acid oxidation
products (Stocker and Keaney, 2004) may also contrib-
ute to the binding of LOX-1 to OxLDL by the introduc-
tion of negative charges.
Reduction in Binding Activity by Mutation
at the Dimer Interface
The severe reduction in the binding activity for the
W150A mutant is remarkable. We do not have any
structural details on the W150A mutant, but the notable
binding reduction is possibly caused by dimer disar-
rangement through resizing of the empty cavity in the
dimer interface based on the present LOX-1 structure
(Figure 5B). The 1H-15N two-dimensional HSQC NMR
spectra for the wild-type and W150A CTLDs were com-
pared. The similar NMR signal dispersion for the wild-
type and W150A CTLDs suggests that the W150A
mutant retains essentially the same CTLD fold as the
wild-type (Figure S3). Therefore, the structural denatur-
ing of W150A CTLD as a possible cause for the severe
reduction in the binding activity is ruled out. This sup-
ports the idea of dimer disarrangement in W150A re-
sulting from disruption of the basic spine structure at
the dimer surface. This view also emphasizes the cru-
cial role of the basic spine in OxLDL recognition dis-
cussed above.
Structural comparison of the ligand binding domains
of crystals grown under acidic and physiological pH
conditions has shown that the single binding domain
does not undergo significant structural changes in re-
sponse to the solution pH. However, dimer arrange-
ment in an asymmetric unit is different under the two
pH conditions. This observation might suggest dimer
disarrangement of LOX-1 in endosomal pH conditions.
As discussed for the W150A mutant, LOX-1 dimer dis-
arrangement would release OxLDL in the endosome. In
considering the significance of the basic spine in
LOX-1 binding to OxLDL as described in the present
work, endosomal pH also titrates acidic groups in
apoB-100 to facilitate OxLDL release from LOX-1. By
analogy with the LDL receptor, LOX-1 is also likely to
be a recycling receptor. The proposed ligand-releasing
mechanism is therefore important in understanding the
possible recycling of LOX-1.
In summary, the crystal structure of LOX-1 presented
in this paper, together with the in vivo binding analyses
with several mutant proteins, demonstrates the signifi-
cance of the basic spine structure on the dimer surface
for OxLDL binding. Based on the consensus model of
the LDL structure, several possible modes of LOX-1
binding to OxLDL are proposed. Very recently, Park and
coworkers have reported the human LOX-1 crystal
structure (Park et al., 2005). Their independent results
are consistent with those presented in this paper.
Further biochemical studies of LOX-1 recognition of
OxLDL will be required to establish a complete under-
standing of this interaction.
Experimental Procedures
Protein Expression and Purification
Human LOX-1 cDNA used in the present work was cloned from
human aortic endothelial cells (HAECs) (Shi et al., 2001). DNA en-coding portions of the extracellular region of human LOX-1 were
engineered for expression in E. coli BL21(DE3) (Stratagene, La
Jolla, CA). These included the C-type lectin-like domain (CTLD; res-
idues 143–273), the complete extracellular region (CTLD-NECK; 61–
273), and the CTLD having a 14 residue NECK domain (CTLD-
NECK14; 129–273). The corresponding gene fragments were
cloned into pET28a (Novagen, Madison, WI) at the NdeI and XhoII
sites. Proteins were expressed as inclusion bodies, denatured, re-
folded, and purified according to the following procedure, adapted
from a similar method reported previously (Llera et al., 2001; Ru-
dolph and Lilie, 1996).
Bacterial cells were grown in M9 minimal medium at 37°C until
the culture reached an optical density at 660 nm of w0.5. Heterolo-
gous expression was induced by the addition of isopropyl-1-thiol-
β-D-galactopyranoside at 1 mM. The cells were then cultured for
an additional 6 hr at 37°C before harvesting. The bacterial cells
were lysed by sonication in a buffer solution containing 50 mM Tris-
HCl (pH 8.0), 400 mM NaCl, 0.1% (v/v) Triton X-100. After centrifu-
gation, the collected cell pellets containing inclusion bodies were
solubilized in 6 M guanidium hydrochloride solution (pH 8.0) in 50
mM Tris-HCl, 50 mM DTT for 4 hr. Solubilized protein in the super-
natant was then diluted slowly into buffer solution containing no
denaturant and 50 mM Tris-HCl (pH 8.5), 0.4 M L-arginine with 5
mM reduced or 0.5 mM oxidized glutathione (GSH/GSSG mixture)
as an oxide shuffling reagent. The protein in the GSH/GSSG mix-
ture was dialyzed against a buffer solution of 25 mM Tris-HCl (pH
7.5), 50 mM NaCl, and was then concentrated on a HisTrap HP
affinity column (Amersham-Pharmacia, Uppsala, Sweden). The pro-
tein was subjected to further purification by gel filtration chroma-
tography (Superdex 75 column, Amersham-Pharmacia). The puri-
fied protein showed the anticipated binding specificity and affinity
for acetylated LDL (AcLDL). This was confirmed by surface plas-
mon resonance (Biacore 2000, Amersham-Pharmacia) by using a
sensor doped with purified LOX-1 protein.
Crystallization and Crystallography
Crystals of the LOX-1 CTLD fragment were grown from an equal
volume mixture of protein solution (8.0 mg/ml protein, 10 mM Tris-
HCl [pH 7.5], 50 mM NaCl) and precipitant solution (100 mM citrate
[pH 3.6]) at 293 K. Crystals of the SeMet derivative of the LOX-1 CTLD
were obtained by slightly modifying the above-described condi-
tions; in brief, protein solution (7.6 mg/ml protein, 10 mM Tris-HCl
[pH 7.5], 50 mM NaCl) was mixed with precipitant solution (100 mM
citrate [pH 4.0–4.2]) containing 20 mM zinc acetate. The NECK14-
CTLD fragment was crystallized at physiological pH from a solution
made from an equal volume of protein solution (4.6 mg/ml protein,
10 mM Tris-HCl [pH 7.5], 400 mM NaCl) and precipitant solution
(100 mM HEPES buffer [pH 7.5], 20% PEG 10 K [Crystal Screen 2
No.38, Hampton Research]) at 277 K.
For the SeMet derivative of the LOX-1 CTLD, diffraction data
were collected at beamline BL40-B2 at Spring-8, Harima, Japan.
The diffraction data were recorded on an ADSC Quantum-4 CCD
scanner and processed by the HKL2000 software package (Ot-
winowski and Minor, 1991). Data for CTLD-NECK14 were collected
at beamline BL-6B in the Photon Factory of the National Laboratory
of High Energy Physics, Tsukuba, Japan. The diffraction data were
recorded on a Rigaku R-AXIS IV2+ imaging plate detector and pro-
cessed by CrystalClear (Molecular Structure Corporation) (Pflu-
grath, 1999). Cryocooling required that the crystals were immersed
in cryoprotectant, comprising a reservoir solution plus 20% (v/v)
ethylene glycol, for several seconds immediately prior to their ex-
posure to a stream of N2 gas at 100 K for data collection.
Phasing and Model Refinement
The structure of LOX-1 CTLD-NECK14 was determined by multiple
anomalous dispersion (MAD) by using a SeMet derivative. Two se-
lenium positions, corresponding to M202 in each subunit, were lo-
cated on anomalous Patterson maps. MAD phases were calculated
by using the program SHARP (de La fortelle and Bricogne, 1997).
The electron density maps computed from the MAD phases al-
lowed us to find the noncrystallographic symmetry (NCS) parame-
ters between the two subunits within the asymmetric unit. The
phases were then improved to 2.0 Å resolution by NCS averaging
Structure
916by using the program DM in CCP4 (CCP4, 1998), followed by C
Catomic model building with the program O (Jones et al., 1991).
Crystallographic refinement was performed with the program CNS D
(Brunger et al., 1998). The crystallographic refinement and manual C
model correction were iterated to convergence (Table 1). m
e
Analytical Ultracentrifugation i
Sedimentation equilibrium experiments were carried out at 20°C r
by using a Beckman Optima XL-1 instrument. LOX-1 CTLD, CTLD- C
NECK14, and the whole extracellular domain were extensively dia- (
lyzed against 10 mM Tris-HCl buffer (pH 7.5) containing 50 mM t
NaCl (CTLD) or 400 mM NaCl (CTLD-NECK14 and the whole extra- l
cellular domain) and were concentrated to 0.1, 0.1, and 0.5 mg
Cml−1, respectively. Equilibrium distributions were analyzed after 27
fhr of centrifugation at 8,000, 15,000, and 20,000 rpm (Beckman An-
c50Ti rotor with double sector centerpiece), respectively. For the cal-
Pculation of molecular mass, the data were fitted to an ideal single
dcomponent model.
h
MDiD-Labeled AcLDL Uptake Assays
DDiD (1,1#-dioctadecyl-3,3,3#,3#-tetramethylindodicarbocyanine per-
Cchlorate)-labeled AcLDL was prepared from human LDL according
pto the previously described method for DiI (1,1#-dioctadecyl-
13,3,3#,3#-tetramethylindocarbocyanine perchlorate) labeling (Ste-
phan and Yurachek, 1993). CHO-K1 cells were grown on coverslips D
and transiently transfected with CFP-tagged native LOX-1, or mu- m
tant LOX-1s. Approximately 48 hr posttransfection, cells were incu- C
bated with DiD-AcLD for 10 min at 37°C. Excess DiD-AcLDL was c
removed by washing gently with fresh medium. The cells were in- B
cubated for another 10 min in order to allow for complete ligand
D
uptake. For live cell imaging, the coverslip was then inverted onto
B
a glass slide with a spacer. Microscopy was performed by using a
FLeica DM IRE2 microscope equipped with a 100×/N.A. 1.4 objec-
(tive and Cool SNAP HQ-cooled CCD camera (Roper Scientific,
pTrenton, NJ) driven by the MetaMorph software (Universal Imaging,
GDowningtown, PA), under conditions that maintained cell activity.
OThe expression level of LOX-1s was examined by CFP fluorescence
aby using an excitation wavelength of 436 nm (0.1 s). DiD-AcLDL
8uptake was analyzed by the amount of DiD-derived fluorescence
excited at 620 nm (0.2 s). Examination was completed within 60 min J
after addition of DiD-AcLDL. Based on the observed fluorescence f
intensities compared with those found for the cells expressing na- t
tive LOX-1, the uptake activities were assessed.
K
M
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